# A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

Source: https://onco.cc/trials/nct07122414/  
OnCo record `nct07122414` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of FL115 in bladder & urothelial cancer, run by Suzhou Forlong Biotechnology Co., Ltd, now recruiting.

## Summary

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer is a phase 1/2 interventional study registered as NCT07122414 by Suzhou Forlong Biotechnology Co., Ltd, with 80 participants planned, started 2024-08-16 and due to reach its primary completion in 2027-10-10. Interventions recorded: FL115 and FL115+BCG.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07122414
- Phase: 1/2
- Setting: A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Intravesical FL115 Alone or in Combination With BCG in Subjects With Non-Muscle Invasive Bladder Cancer, Including Dose Escalation and Cohort Expansion
- Sponsor: Suzhou Forlong Biotechnology Co., Ltd
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07122414: https://clinicaltrials.gov/study/NCT07122414

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- companies: [Suzhou Forlong Biotechnology](https://onco.cc/companies/suzhou-forlong-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/nct07122414.json